Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous interleukin-12-expressing acute myeloid leukemia cells
- Development stage
- Phase 1
- Lead developer
- University Health Network
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Infusion
01
Overview
Autologous interleukin-12-expressing acute myeloid leukemia cells is an investigational cell and gene therapy designed for acute myeloid leukemia (AML). This therapy involves genetically engineering a patient's own (autologous) AML cells to express and secrete Interleukin-12 (IL-12) using a lentiviral vector. When re-infused, these modified cells act as an in situ vaccine, stimulating a potent anti-tumor immune response. The secreted IL-12 activates the patient's immune system, leading to the recognition and elimination of leukemia cells, including those not expressing IL-12. This approach aims to induce long-term immunological memory against AML and has shown preclinical promise in inhibiting angiogenesis and inducing apoptosis in AML cells. It is currently in Phase I clinical trials for patients with relapsed or high-risk AML.
- Other names
- IL-12-engineered AML cellsIL12-engineered AML cellsIL 12-engineered AML cellsIL-12-secreting autologous AML cellsIL12-secreting autologous AML cellsIL 12-secreting autologous AML cells
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on autologous interleukin-12-expressing acute myeloid leukemia cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous interleukin-12-expressing acute myeloid leukemia cells.